Carnegie Mellon University Takes Position in Predictive Oncology Inc. (NASDAQ:POAI)

Carnegie Mellon University acquired a new position in Predictive Oncology Inc. (NASDAQ:POAI) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 10,358 shares of the medical instruments supplier’s stock, valued at approximately $34,000. Predictive Oncology makes up approximately 0.0% of Carnegie Mellon University’s investment portfolio, making the stock its 5th biggest holding.

Separately, Raymond James & Associates acquired a new stake in shares of Predictive Oncology in the third quarter valued at $378,000. 9.04% of the stock is owned by institutional investors and hedge funds.

Predictive Oncology Price Performance

Shares of POAI traded up $0.32 during mid-day trading on Thursday, hitting $1.66. The company’s stock had a trading volume of 246,542 shares, compared to its average volume of 29,666. The firm has a 50-day moving average price of $2.48 and a 200 day moving average price of $2.92. Predictive Oncology Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $7.12. The stock has a market capitalization of $6.74 million, a price-to-earnings ratio of -0.48 and a beta of 1.28.

Predictive Oncology (NASDAQ:POAI) last posted its quarterly earnings results on Thursday, March 28th. The medical instruments supplier reported ($0.85) earnings per share (EPS) for the quarter. The business had revenue of $0.34 million during the quarter. Predictive Oncology had a negative return on equity of 104.21% and a negative net margin of 785.62%.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.